Who Owns Jardiance?
Jardiance is owned by Boehringer Ingelheim, the private German pharmaceutical company, and co-marketed with Eli Lilly under a diabetes alliance formed in 2011. The empagliflozin tablet won US FDA approval in 2014 for type 2 diabetes and added heart failure and chronic kidney disease indications, generating approximately $8.9 billion in combined global revenue in fiscal 2025 and ranking as the best-selling SGLT2 inhibitor.
Parent Company
Founded
2014
Status
Private
Jardiance Timeline
Who Owns Jardiance?
- Parent Company: Boehringer Ingelheim
- Ownership Type: Joint venture
- Company Type: Privately Held
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Jardiance | Boehringer Ingelheim | Joint venture |
Where to Buy
Disclosure: We may earn commission from purchases
Jardiance on AmazonAdvertisement
History of Jardiance
- Founded: 2014
- Founders: Boehringer Ingelheim, Eli Lilly
Boehringer Ingelheim developed empagliflozin as an SGLT2 inhibitor during the 2000s and brought it into the Lilly diabetes alliance. The FDA approved Jardiance for type 2 diabetes in August 2014, the third SGLT2 inhibitor to reach the US market after Invokana and Farxiga.
The 2015 EMPA-REG OUTCOME trial produced a landmark result: empagliflozin reduced cardiovascular death by 38 percent, the first diabetes drug to show mortality benefit. The FDA added a cardiovascular indication in 2016, transforming Jardiance from a glucose-lowering agent into a cardio-protective drug.
Heart failure approval followed in 2021 and 2022 covering both reduced and preserved ejection fraction, and chronic kidney disease indication arrived in 2023. Each expansion widened the patient base far beyond diabetes, driving sales from under $2 billion to approximately $8.9 billion in fiscal 2025.
Jardiance now leads the SGLT2 class globally, outselling Farxiga and Invokana, and its multi-indication footprint established the template for modern diabetes drug development.
Advertisement
About Boehringer Ingelheim
Is Boehringer Ingelheim family-owned?
Yes. Boehringer Ingelheim has been continuously family-owned since 1885, held by the Boehringer, von Baumbach, and Engelhorn families. It has never listed shares publicly and states it intends to remain independent.
Is Boehringer Ingelheim publicly traded?
No. Boehringer Ingelheim is a private company with no stock listing. It is one of the world's largest privately held pharmaceutical companies and cannot be invested in through public markets.
When was Boehringer Ingelheim founded?
Boehringer Ingelheim was founded in 1885 in Ingelheim am Rhein, Germany, initially producing tartaric acid. It expanded into pharmaceuticals in the late 19th century and has operated for more than 140 years.
Who founded Boehringer Ingelheim?
Albert Boehringer founded the company in 1885. His descendants across the Boehringer, von Baumbach, and Engelhorn families still own it, now in the fifth and sixth generations.
Advertisement
What is Boehringer Ingelheim's market position?
Boehringer Ingelheim is a top-20 global pharmaceutical company with 2025 net sales of EUR 27.75 billion. Its largest product is Jardiance at EUR 8.8 billion, and it is also a top-tier animal health company led by the NexGard franchise.
Who leads Boehringer Ingelheim?
Shashank Deshpande has been chairman of the Board of Managing Directors since mid-2025, succeeding Hubertus von Baumbach, a fifth-generation family member who moved to the shareholders' committee. Deshpande previously led the Human Pharma division.
- Founded: 1885
- Headquarters: Ingelheim am Rhein, Rhineland-Palatinate, Germany
- Company Type: Privately Held
- Revenue: EUR 27.75 billion (FY2025)
- Employees: Approximately 54,300
Where Is Jardiance Made / Based?
- Headquarters: Ingelheim am Rhein, Germany (Boehringer Ingelheim)
- Manufacturing / Operations: Germany, United States, China
Jardiance Categories & Tags
Jardiance Recalls & Controversies
Jardiance has faced no major recalls. Label warnings cover genital infections, ketoacidosis, and dehydration common to the SGLT2 class. The FDA mandated ketoacidosis labeling updates after post-market reports across the class.
The brand has faced pricing scrutiny in the US, where it was selected for Medicare price negotiation under the Inflation Reduction Act, with negotiated pricing taking effect from 2026.
Advertisement
Brands Owned by Boehringer Ingelheim
Healthcare PharmaceuticalsBoehringer Ingelheim
Owned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
pharmaceuticalsprescription-drugsanimal-health
Healthcare PharmaceuticalsTradjenta
Owned by Boehringer Ingelheim
Linagliptin DPP-4 inhibitor for type 2 diabetes, developed by Boehringer Ingelheim and co-marketed with Eli Lilly since its 2011 FDA approval.
diabetestype-2-diabetesdpp-4-inhibitor
Jardiance Ownership: Pros & Cons
Advantages
- +Best-selling SGLT2 inhibitor globally
- +Multi-indication coverage across diabetes, heart failure, and kidney disease
- +Landmark cardiovascular outcome data supporting prescribing
- +Dual marketing reach through Boehringer and Lilly networks
- +Approximately $8.9 billion annual revenue
Considerations
- -Patent expiry approaching with generics expected from 2025 onward
- -Medicare price negotiation impacts US revenue from 2026
- -GLP-1 dominance pressures the diabetes indication
- -Two-company structure complicates strategic decisions
- -Single molecule carries the entire brand value
Advertisement
Frequently Asked Questions About Jardiance
Sources & Further Reading
Advertisement
Competitors to Jardiance
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Astrazeneca | United Kingdom (parent AstraZeneca) | 2014 | Market leader | Global | All Genders | |
| Astrazeneca | United Kingdom | 1999 | Market leader | Global | All Genders | |
| Astrazeneca | United Kingdom (parent AstraZeneca) | 2012 | Niche | Global | All Genders | |
| Eli Lilly | USA | 1876 | Market leader | Global | All Genders | |
| Sanofi | France | 1973 | Market leader | Global | All Genders | |
| Boehringer Ingelheim | Germany | 1885 | Market leader | Global | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsFarxiga
Owned by AstraZeneca PLC
Dapagliflozin SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease, owned by AstraZeneca since its 2014 US launch.
pharmaceuticalsprescription-drugsdiabetes
Healthcare PharmaceuticalsAstraZeneca
Owned by AstraZeneca PLC
British-Swedish pharmaceutical brand behind Tagrisso and Farxiga, owned by publicly traded AstraZeneca PLC formed by merger in 1999.
pharmaceuticalsprescription-drugsoncology
Healthcare PharmaceuticalsBydureon
Owned by AstraZeneca PLC
Exenatide extended-release weekly injectable for type 2 diabetes, owned by AstraZeneca since the 2012 Amylin Pharmaceuticals acquisition.
pharmaceuticalsprescription-drugsdiabetes
Healthcare PharmaceuticalsEli Lilly
Owned by Eli Lilly and Company
American pharmaceutical brand behind Mounjaro and Zepbound, owned by publicly traded Eli Lilly and Company founded in Indianapolis in 1876.
pharmaceuticalsprescription-drugsdiabetes
Healthcare PharmaceuticalsSanofi
Owned by Sanofi
French pharmaceutical brand behind Lantus and Dupixent, owned by publicly traded Sanofi SA founded in Paris in 1973.
pharmaceuticalsprescription-drugsvaccines
Healthcare PharmaceuticalsBoehringer Ingelheim
Owned by Boehringer Ingelheim
German family-owned pharmaceutical brand behind Jardiance and Spiriva, founded in 1885 and still controlled by the Boehringer family.
pharmaceuticalsprescription-drugsanimal-health
Competitive Analysis
Market Positioning: Jardiance competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Jardiance
Looking for brands with different ownership structures? These similar brands are not owned by Boehringer Ingelheim, giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsFarxiga
Owned by AstraZeneca PLC
Dapagliflozin SGLT2 inhibitor approved for type 2 diabetes, heart failure, and chronic kidney disease, owned by AstraZeneca since its 2014 US launch.
pharmaceuticalsprescription-drugsdiabetes
Publicly Traded
Farxiga is owned by AstraZeneca PLC, a public company, a different structure than Jardiance's parent.
Healthcare PharmaceuticalsAstraZeneca
Owned by AstraZeneca PLC
British-Swedish pharmaceutical brand behind Tagrisso and Farxiga, owned by publicly traded AstraZeneca PLC formed by merger in 1999.
pharmaceuticalsprescription-drugsoncology
Publicly Traded
AstraZeneca operates independently without a large parent corporation.
Healthcare PharmaceuticalsEli Lilly
Owned by Eli Lilly and Company
American pharmaceutical brand behind Mounjaro and Zepbound, owned by publicly traded Eli Lilly and Company founded in Indianapolis in 1876.
pharmaceuticalsprescription-drugsdiabetes
Publicly Traded
Eli Lilly operates independently without a large parent corporation.
Healthcare PharmaceuticalsSanofi
Owned by Sanofi
French pharmaceutical brand behind Lantus and Dupixent, owned by publicly traded Sanofi SA founded in Paris in 1973.
pharmaceuticalsprescription-drugsvaccines
Publicly Traded
Sanofi operates independently without a large parent corporation.
Healthcare PharmaceuticalsNovo Nordisk
Owned by Novo Nordisk
Danish pharmaceutical company specializing in diabetes care and obesity treatment. Founded in 1923, headquartered in Bagsvaerd, Denmark. World leader in diabetes care and a leader in obesity treatment with Ozempic, Wegovy, and the investigational CagriSema. CEO Lars Fruergaard Jorgensen departed in March 2025; interim leadership under board chairman Helge Lund until a permanent CEO is appointed.
pharmaceuticalsdiabetesobesity
Publicly Traded
Novo Nordisk operates independently without a large parent corporation.
Healthcare PharmaceuticalsAmgen
Owned by Amgen Inc.
Master biotechnology brand of Amgen Inc., the world's largest independent biotech, covering its full portfolio of biologic medicines.
biotechnologypharmaceuticalsbiologics
Publicly Traded
Amgen operates independently without a large parent corporation.
Jobs at Boehringer Ingelheim
Advertisement
Latest News About Jardiance
Related Articles About Jardiance
View more articles
Health
The Pharmaceutical Giants Behind Common Medicines
Eli Lilly is now #1 pharma ($65.2B, Mounjaro + Zepbound). Novo Nordisk has 59.6% GLP-1 share. Merck's Keytruda is $31.7B. Pfizer faces a $20B patent cliff. Discover who makes your medicines. Explore our database.
Who Brands StaffNov 6, 2026
PharmaceuticalsEli LillyNovo Nordisk
Health
Generic vs Brand Name Drugs: Same Company or Different
Teva is the world's largest generic drugmaker (~6% US share). Sandoz was spun off Novartis in 2023. Viatris came from Mylan + Pfizer's Upjohn. Pfizer itself holds hundreds of ANDAs. Explore our database.
Who Brands StaffOct 30, 2026
Generic DrugsBrand NamePharmaceuticals
Health
Dental Brand Ownership Beyond Colgate and Crest
Colgate holds 41.3% global toothpaste share. P&G (Crest, Oral-B) has 14.1%. Haleon (Sensodyne) has 4.4%. Church & Dwight is the only independent at scale. The oral care market is $47.2B. Explore our database.
Who Brands StaffNov 12, 2026
ColgateCrestOral B
Advertisement
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandmedical-devices
Abbott Medical Devices
Abbott Laboratories' medical device business spanning cardiovascular, diabetes care (FreeStyle Libre), neuromodulation, and structural heart, generating roughly $20 billion annually.
Brand in Healthcare & Pharmaceuticals
cardiovasculardiabetes-care
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization